Moderna2026-10-02 00:09:41Moderna to Join Nasdaq-100 Before Oct. 9 Open, Replacing Warner Bros. DiscoveryChainCatcher reported that Moderna will become a constituent of the Nasdaq-100 before the market opens on Friday, Oct. 9. The company is set to replace Warner Bros. Discovery in the index. The brief did not provide additional details on the index adjustment or the reason for the change. The update was published as a 7x24 news flash.20
U.S. stocks2026-09-30 13:31:44U.S. stocks open higher as Moderna falls 7.1% and Robinhood gains 5.4%U.S. stocks opened in positive territory, according to market data cited by ChainCatcher from Gate. The Dow Jones Industrial Average rose 0.2% at the open, while the S&P 500 added 0.3% and the Nasdaq gained 0.4%. Among individual names, Moderna fell 7.1% after Citigroup cut its rating on the company to Sell from Neutral. Robinhood rose 5.4% after launching a 24-hour weekend U.S. stock trading service. Boeing also moved higher, gaining 2.3% after securing the U.S. Navy’s next-generation fighter jet contract. The move left the major indexes in the green at the start of trading, while stock-specific catalysts drove sharper swings in several widely watched names.00
cancer vaccin2026-09-08 02:20:09Tempus AI Could See Over $600M in Annual Revenue from Cancer Vaccine Sequencing, Analysts SayModerna and Merck's personalized cancer vaccines have added over $50 billion in market value to the two drugmakers. The diagnostic sequencing process behind these vaccines is emerging as a new investment opportunity. Tempus AI, as a sequencing partner for the Moderna-Merck vaccine, could benefit if the vaccine is approved. Piper Sandler estimates the melanoma vaccine alone could generate at least $50 million in annual sequencing revenue, while BTIG analyst Mark Massaro projects the figure could exceed $600 million. The post-treatment cancer recurrence monitoring market via blood tests is seen as a multi-billion-dollar opportunity, but Natera currently dominates. However, uncertainties remain in the mRNA cancer vaccine field, and pharma companies may internalize some sequencing work in the future.960
Binance2026-09-02 08:33:01Binance to List Four bStocks Tokenized Security Pairs: CrowdStrike, Moderna, SQQQ, SeagateBinance will list four bStocks tokenized security trading pairs on September 2, 2026, at 20:00 UTC+8: CrowdStrike (CRWDB), Moderna (MRNAB), ProShares UltraPro Short QQQ (SQQQB), and Seagate (STXB). Spot algo trading bots go live simultaneously, with smart holdings bots enabled within 24 hours. Users can convert bStocks to BTC, USDT, or other tokens fee-free for the first hour. Zero maker fees on the four pairs until October 1, 2026, 07:59 UTC+8.980
Binance2026-09-02 08:36:07Binance to List Four bStocks Tokenized Securities Trading Pairs on September 2Binance will list bStocks tokenized securities trading pairs for CrowdStrike (CRWDB), Moderna (MRNAB), ProShares UltraPro Short QQQ (SQQQB), and Seagate (STXB) at 20:00 UTC+8 on September 2, 2026. The exchange will also enable spot algorithmic trading bots and smart position management bots. Within one hour after listing, users can convert bStocks to BTC, USDT, or other tokens via Flash Convert with zero fees.980
Biotech2026-08-26 01:46:35Biotech shares rally across U.S. and Hong Kong as Moderna jumps 14% and CanSino rises more than 17%Biotech stocks posted sharp gains across U.S. and Hong Kong markets on Aug. 26, according to market data cited by BlockBeats. Moderna (MRNA) closed up 14.36% in U.S. trading with turnover reaching $7.636 billion, while Merck (MRK) gained 3.84%. The move followed a recent joint announcement from Moderna and Merck that their first personalized mRNA cancer therapy, intismeran autogene, succeeded in a global Phase III clinical trial for high-risk melanoma. After that update, several major banks raised their price targets on Moderna, including Bank of America, Piper Sandler, Goldman Sachs, JPMorgan, and Barclays. In Hong Kong trading, CanSino Biologics rose 17% after the open, while Innovent Biologics gained more than 10%, Everest Medicines rose more than 7%, Akeso climbed more than 6%, and RemeGen advanced more than 4%. CanSino also said its subsidiary CanSino Shanghai had formally signed a strategic framework agreement with DeepVessel Biopharma to jointly develop and commercialize personalized therapeutic mRNA tumor vaccines.990
JPMorgan2026-08-21 03:32:49JPMorgan keeps bearish view on Moderna, says INT melanoma win was already priced inJPMorgan said in an Aug. 19 research note that Moderna and Merck’s individualized neoantigen therapy, referred to as INT, met its primary endpoint in adjuvant melanoma, with recurrence-free survival showing a significant improvement. The key secondary endpoint, distant metastasis-free survival, also met the bar. Even so, the bank argued the result was widely expected and had already been reflected in Moderna’s share price before the update was released. The firm kept its Underweight rating and a $40 price target on Moderna, versus a current share price of $63 cited in the note, implying 36% downside. JPMorgan’s view is that the clinical success of INT in adjuvant melanoma is no longer the main valuation question. Instead, the next leg of value depends on whether the therapy can show similar efficacy across a broader set of tumor types. JPMorgan said it had already assigned an 85% probability of success to the phase III melanoma study, based on prior phase IIb data and the biological rationale of the approach in cancer immunotherapy. The bank added that adjuvant melanoma is a relatively small indication, and that Moderna’s roughly $25 billion market value already includes expectations for approval in this setting. It said future data in non-melanoma indications will be more important for the company’s valuation.1090
Moderna2026-08-21 02:05:21Moderna melanoma Phase 3 readout puts AI-driven drug development deeper into clinical and manufacturing workflowsModerna and Merck said on Aug. 19 that the Phase 3 INTerpath-001 trial delivered a positive topline readout in resected Stage IIB-IV melanoma, with Intismeran plus Keytruda showing statistically significant and clinically meaningful improvement in recurrence-free survival and distant metastasis-free survival versus Keytruda alone. The study enrolled 1,137 patients, but Moderna has not yet released the hazard ratios, absolute recurrence-rate differences, or overall survival data, so the only firm conclusion for now is that the Phase 3 study met its interim bar. The trial will continue rather than stop early. The report argues that the bigger story is operational. Intismeran is not a one-formula product for every patient. The therapy is built from each patient’s tumor and blood genetic information, with up to 34 neoantigens selected before a personalized mRNA treatment is produced. Moderna’s Maestro digital system coordinates clinical operations, manufacturing, quality control, and logistics across separate production batches. The article also points to upstream data work by Personalis, whose tumor analysis platform has been used by Moderna and Merck since the early V940/mRNA-4157 program, and notes Tempus AI’s planned acquisition of Personalis at about $1.5 billion enterprise value. It pairs that development with Anthropic’s recent protein-design experiment to show a broader shift: AI is moving out of stand-alone software and into real-world research, lab, production, and clinical processes.1450
